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Abstract
Background: Even though ovarian tumors are not generally considered estrogen-sensitive, estrogens may still
have an impact on ovarian tumor progression. The recently identified trans-membrane estrogen receptor GPER is
involved in rapid estrogen signaling. Furthermore, it binds selective estrogen receptor modulators with agonistic
effect, which could explain tamoxifen controversies.
Methods: GPER mRNA was assayed with quantitative real-time PCR (qPCR) in 42 primary ovarian tumors and 7
ovarian cancer cell lines. ERa and ERb mRNA were analyzed for comparison. GPER protein was semi-quantified with
densitometric scanning of Western blots and its tissue distribution analyzed with immunohistochemistry (IHC) in 40
ovarian tumors. In addition, IHC was evaluated in a tissue microarray (TMA) of 150 primary malignant ovarian
tumors.
Results: All tumor samples contained GPER mRNA. The content of mRNA was not different between benign and
malignant tumors, but one third of malignant samples over-expressed GPER mRNA. The content of ERa mRNA was
higher in malignant than in benign tumors, whereas ERb mRNA was higher in benign than in malignant tumors.
GPER mRNA was detected in all seven ovarian cancer cell lines with highest levels in TOV21G and TOV112D cells.
Similar expression pattern was seen for ERb mRNA. Western blot demonstrated GPER protein in all tumor samples.
Semi-quantification showed no difference between benign and malignant tumors, but about one third of
malignant samples over-expressed GPER protein. GPER staining was localized mainly in epithelial cells. In the TMA
study we found no correlation between GPER staining and clinical stage, histological grade or patient survival.
Conclusions: GPER mRNA as well as GPER protein is present in both benign and malignant ovarian tumor tissue.
About one third of malignant tumors over-expressed both GPER mRNA and protein. This, however, correlated
neither with histological or clinical parameters nor with patient survival.
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Background
Epidemiologic data suggest on the one hand that estra-
diol taken as oral contraceptive in the premenopause
decreases the risk of ovarian cancer, while taken as hor-
mone therapy in the postmenopause increases that risk.
From a clinical perspective, development and progres-
sion of ovarian tumors are not generally considered
estrogen sensitive, as is the case for breast and
endometrial cancer. However, some experimental data
challenge this perception. Patients with ovarian tumors
have elevated blood levels of estradiol, and estrogenic
steroids stimulate proliferation in several ovarian cancer
cell lines [1]. Also, apoptosis was reduced by estradiol in
immortalized ovarian surface epithelial cells via Akt
mediated up-regulation of bcl-2, an anti-apoptotic gene
[2]. These effects of estradiol involved the nuclear estro-
gen receptor a (ERa), and distribution of ERa in malig-
nant ovarian tumor tissue overlapped with a marker for
cell proliferation as well as with lower apoptotic activity
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[3]. In contrast, the other nuclear estrogen receptor ERb
inhibited cell growth and induced apoptosis [4].
The two nuclear estrogen receptors ERa and ERb are
present in normal ovarian surface epithelial cells as well
as in ovarian tumors and cancer cell lines. A general
feature, which has been documented in numerous
tumor types, including ovarian, breast, prostatic, lung
and colorectal cancer is an increase of ERa and a
decrease of ERb in malignant as compared to corre-
sponding benign tumors [5].
The transmembrane G protein-coupled receptor 30
(GPR30) was recently reported to bind estradiol with
high affinity, KD 3-6 nmol/L, i.e. 10 times higher than
that of ERa [6], and was re-named G protein-coupled
estrogen receptor 1 (GPER). It is localized in the cell
membrane as well as in intracellular membranes [7,8].
GPER is widely expressed in the human body, both in
normal and pathological tissues. In addition to estradiol,
this receptor binds selective estrogen receptor modula-
tors (SERM), e.g. tamoxifen, as well as antagonists, e.g.
ICI 182780, creating an agonistic response [6]. Down-
stream signaling involves second messengers like MAP
and PI3 kinases, as well as trans-activation of the epider-
mal growth factor receptor [9].
This study of GPER in primary ovarian tumors and
ovarian cancer cell lines was partly initiated because
SERM molecules, like tamoxifen, have come in use as
adjuvant therapy in patients with ovarian cancer, and
these compounds are GPER agonists. A minority of
these patients, about 10-15%, responds clinically to
treatment with tamoxifen, but whether this effect
involves ERa, ERb, GPER, or all of them, remains still
an open question. In fact, both GPER and ERa along
with an intact EGFR signaling were required for estro-
gen-stimulated proliferation of ovarian cancer cells [10].
In contrast, a recent paper by Gao et al. suggests that
activation of epithelial GPER inhibits uterine growth by
paracrine inhibition of stromal ERa signaling [11].
These observations, together with complex and tissue-
specific responses to SERMs, suggest intricate interac-
tions between the nuclear and membrane estrogen
receptors.
We assayed GPER mRNA and GPER protein in
benign and malignant tumors, analyzed GPER protein
distribution in the tumor tissue, and also explored the
possibility that GPER expression correlates with tumor
histology or survival in patients with ovarian cancer.
Methods
Tumor tissue samples for real-time PCR, western blot and
immunohistochemistry
Ovarian tumor tissue samples (n = 42) were obtained at
operation, Department of Obstetrics and Gynecology,
Lund University Hospital, during 2001-2007. The
oncologic surgeon selected the precise area for tumor
biopsies. The samples were cut in 5 × 5 × 5 mm cubes,
quick frozen on dry ice, and stored at -80°C. Tumors
were sent for routine histopathological examination.
Histological parameters were subsequently re-evaluated
by one of us (A.E.), and classification of the material is
shown in Table 1. Archival paraffin embedded section
were retrieved for immune histochemistry. The study
was approved by the Ethical Review Board at Lund Uni-
versity Hospital.
Tumor tissue samples for tissue micro-array (TMA)
construction
Formalin-fixed and paraffin embedded archival tissues
from primary malignant epithelial ovarian tumors (n =
154) were used. All cases were histopathologically re-
evaluated and tumor content verified in hematoxylin-
eosin stained slides. This material and TMA construc-
tion has previously been detailed in several publications
[12-16].
Ovarian cancer cell lines
Seven human cell lines all derived from epithelial ovar-
ian adenocarcinomas were cultured under specified con-
ditions on uncoated plastic. TOV21G, TOV112D,
SKOV-3, OVCAR-3, ES-2 were grown according to
ATCC recommendations http://www.lgcstandards-atcc.
org/. SKOV-3ip (a gift from Tumor Immunology, Lund
University, Sweden), and HEY-TG (a gift from M.D.
Anderson Cancer Institute, Houston, TX, USA) were
cultured in M199 with 10% FBS as we previously
described [17]. Culture media and supplements were
obtained from Invitrogen, Gibco (Carlsbad, CA, USA).
Gene expression
Total RNA was extracted from about 125 mg frozen
ovarian tumor tissue. The tissue was homogenized in
Trizol 50 mg/mL (Invitrogen, Carlsbad, CA) using rotat-
ing-knives (Polytron). Total RNA from harvested cells
was extracted using EZNA Total RNA Kit™ (OMEGA
Bio-Tec, Doraville, GA, USA). All RNA samples were
evaluated for concentration and purity by NanoDrop
Table 1 Histopathology of primary ovarian tumors used
in qPCR and Western blot
Serous Mucinous Endometrioid Total
BENIGN 4 5 9
BORDERLINE 6 5 11
GRADE 1 6 2 8
GRADE 2 1 3 4
GRADE 3 5 5 10
Total 21 13 8 42
Kolkova et al. Journal of Ovarian Research 2012, 5:9
http://www.ovarianresearch.com/content/5/1/9
Page 2 of 11
Spectrophotometer ND-1000 (Saveen Werner, Lim-
hamn, Sweden) as well as quality by 2% agarose gel elec-
trophoresis. For reverse transcription to cDNA we used
TaqMan Reverse Transcription Reagents (Applied Bio-
systems, Foster City, CA, USA). The final concentration
of cDNA was 10 ng/μL (+/- 7%).
Real-time PCR was performed using ABI PRISM 7000
(Applied Biosystems) with following pre-manufactured
assays (Applied Biosystems): Hs00173506_m1 (GPER),
Hs00174860_m1 (ERa), Hs00230957_m1 (ERb),
Hs99999903_m1 b-actin(ACTB) and Hs99999142_m1
cyclin-dependent kinase inhibitor 1A (CDKN1A). Sev-
eral reference genes were evaluated both in tumor tissue
samples and in the cell lines for minimal variation
between groups and cell lines. CDKN1A was chosen for
the tumor samples and ACTB for the cell lines. Quanti-
fication employed a calibration curve obtained by serial
dilutions of the template DNA (80 - 0.08 ng). Results
are expressed as relative values.
Western blot and semi-quantification of GPER protein
Ovarian tumor tissue (65-75 mg), HEK-293 cells (negative
control), SKBr-3 and MCF-7 cells (positive controls) were
disintegrated in QIAGEN TissueLyser (Retsch Technology
GmbH, Haan, Germany) and membrane proteins prepared
as described [18]. Each membrane fraction (20 μg total
protein) was analyzed with Western blot [18]. We used
the anti-human goat GPER antibody (AF5534, R&D sys-
tems Inc., Minneapolis, MN, USA). The immunogen was
a 62 amino acid E. coli derived peptide, which constitutes
the extra-cellular N-terminal of human GPER. The speci-
fic band was scanned (Syngene, Cambridge, UK) and the
density (Gene Tools, Philomath, Oregon, USA) was taken
as a semi-quantitative measure of GPER protein.
Immunohistochemistry of GPER
Sections were de-parafinized and re-hydrated, antigen
retrieved in Buffer Dako S 1699 under pressure at 121°
C, and finally endogenous peroxidase blocked by Dako S
2023 solution. IHC staining was performed in Autostai-
ner Plus (Dako A/S, Glostrup, Denmark) using as pri-
mary antibody either goat anti-GPER (AF5534) or
mouse monoclonal anti-ERa antibody (M 7047, Dako)
both diluted 1:50. Biotinylized anti-goat and anti-mouse
antibodies (Dako) respectively, were used as secondary
antibodies. A streptavidin-peroxidase complex was used
for detection, and peroxidase activity visualized by Dako
Real™ Detection System (K5001, Dako). Non-immune
goat or mouse IgG (Dako) replaced the primary anti-
body as negative control.
Semi-quantification of immuno staining in TMA slides
For assessment of GPER expression staining intensity as
well as the fraction of positive cells we used a
modification of a previously described semi-quantitative
scoring system [19]. Staining intensity (I) was categor-
ized as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong).
The fraction of positive cells (F), which took into
account both membrane and cytoplasmic staining in the
tumor cells, was classified as 0 (0-1%), 1 (2-10%), 2 (11-
50%) and 3 (> 50%). A staining score was then created
by I × F, which ranged from 0 to 9. For statistical pur-
poses the staining score was further categorized as nega-
tive (0-1), weak (2-3), and strong (4-9). The immuno
staining was assessed by two independent observers (Z.
K., A.E.). The observers had minor disagreement in
about 10% cases. These samples were re-evaluated by
both observers in order to reach a consensus.
Statistical methods
Data are presented as scatter box plots with median and
percentiles. The Mann-Whitney and Kruskal-Wallis test
were used to evaluate the significance of differences
between groups. Spearman’s test was used to assess the
rank correlation between different mRNA assays and
staining. Jonckheere’s test was performed evaluate the
significance of trends between groups. Fisher’s exact test
was used to compare number of samples with over-
expression between groups. Kaplan-Meier analysis and
log rank test were used to analyze differences in overall
survival in patients with ovarian cancer stratified accord-
ing to GPER expression. All tests were two-sided and
5% level of significance was used.
Results
GPER mRNA in ovarian tumors
All primary ovarian tumor samples i.e. benign, border-
line and malignant, expressed GPER mRNA (Figure 1).
Serous, mucinous, and endometrioid tumors are pre-
sented together, since no consistent difference in expres-
sion was found between these histological types. The
level of GPER mRNA was not different between the
benign/borderline and malignant groups. Furthermore,
there was no relation to loss of differentiation within
the malignant group. However, the number of samples
expressing GPER mRNA above the arbitrary cut-off 0.5
was significantly higher in the malignant group 6/22
(27%) as compared to the benign/borderline groups 0/
20 (0%).
ERa mRNA and ERb mRNA in ovarian tumors
For comparison, the same set of samples was analyzed
for ERa and ERb mRNA (Figure 2). The content of ERa
mRNA was higher in truly malignant tumors than in
benign/borderline tumors, whereas the content of ERb
mRNA was lower in malignant than in benign/border-
line tumors. These divergent patterns of the nuclear ERs
were unlike that of GPER mRNA. However, 5 out of 6
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GPER high-expressers had also high levels of ERa
mRNA. GPER mRNA and ERa mRNA showed a weak
correlation (rho = 0.5; p = 0.001).
GPER, ERa and ERb mRNA in ovarian cancer cell lines
All seven ovarian cancer cell lines expressed GPER
mRNA. Highest expression was seen in TOV-112D and
TOV-21 G, whereas the other five cell lines expressed at a
lower level (Figure 3). ERa mRNA and ERb mRNA were
analyzed for comparison. All seven cell lines expressed
ERb mRNA, and the pattern had similarities to that of
GPER mRNA with high expression mainly in TOV-112D
but also in TOV-21 G (Figure 3). In contrast, ERa mRNA
was detected at a significant level in only two of the cell
lines, SKOV-3ip and HEY-TG (Figure 3).
GPER protein in ovarian tumors
Western blot detected GPER protein as a single band of
varying intensity at 54 kDa in all primary ovarian
tumors (Figure 4A). In addition to the samples used for
qPCR, another two grade 3 tumors could be included in
this analysis. GPER protein was semi-quantified by den-
sitometric scanning of the band for each sample, and
results are presented according to histological differen-
tiation (Figure 4B). We found no significant difference
between the malignant group and the benign/borderline
group (Mann-Whitney test, Kruskal-Wallis).
However, the malignant tumors showed greater varia-
tion in the tissue content of GPER protein than did the
benign/borderline tumors. In fact, the number of samples
with GPER above the arbitrary cut-off level 500 was signif-
icantly higher in the malignant group 10/24 (42%) than in
the benign/borderline group 1/16 (6%). High expressing
samples appeared in all three malignant grades groups,
suggesting no relation to loss of histological differentiation.
Tissue distribution of GPER protein in ovarian tumors
IHC analysis revealed that GPER was localized mainly to
epithelial tumor cells (Figure 5). Staining was focal and
often strongest in tumor cells close to the stroma. Some
malignant samples had stronger staining intensity than
benign and borderline samples. Both membrane and
cytoplasmic staining was observed in the tumor cells.
Staining was also noted in single, possibly migratory,
cells in the stroma.
Semi-quantification of GPER in TMA and relation to
clinical outcome
GPER expression could be evaluated in 150/154 (97%)
primary tumors. Evaluation included only staining in
Figure 1 GPER gene expression in ovarian tumors GPER mRNA, normalized to CDKN1A mRNA, in ovarian tumor tissue samples (n =
42). Histology was classified as benign (BE), borderline (BO), and malignant. The latter group was further split according to differentiation as
grade 1 (G1), grade 2 (G2), and grade 3 (G3). G1 and G2 are presented together due to low number of samples in G2. The number of samples
(n) in each group is indicated in the figure. GPER mRNA levels were not different between the groups, but the number of samples with high
GPER mRNA levels (> 0.5 arbitrary cut-off) was higher in malignant (6/22) than in benign/borderline samples (0/20), (p = 0.02; Fisher’s exact test).
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tumor cells. According to our staining score 100 sam-
ples (67%) were negative (score 0-1), 27 samples (18%)
showed weak positivity, and 23 (15%) strong positivity
(Figure 6A). Positive GPER staining correlated neither
with histological grade or type nor with clinical stage.
Furthermore, positive staining was not predictive for
overall survival of the patients (Figure 6B). Also, staining
intensity and positive cell fraction, when evaluated sepa-
rately, lacked correlation with the histological and clini-
cal parameters. In order to verify sensitivity and
Figure 2 ERa and ERb gene expressions in ovarian tumors ERa mRNA and ERb mRNA, normalized to CDKN1A mRNA, in the same set
of tumor samples as in Figure 1. Abbreviations are as in Figure 1. ERa mRNA was higher in malignant than in benign/borderline samples (p
= 0.01), whereas ERb mRNA was lower in malignant than in benign/borderline samples (p < 0.0001).
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Figure 3 GPER, ERa and ERb gene expression in ovarian cancer cell lines GPER, ERa, and ERb mRNAs were normalized to
corresponding b-actin mRNA in seven ovarian cancer cell lines (analyzed in 4-6 wells). Cell lines are arranged in order of declining GPER
mRNA level. All cell lines expressed GPER mRNA and ERb mRNA with highest levels in TOV21G and TOV112D. ERa mRNA was not detected in
TOV21G, TOV112D, OVCAR3, ES2, and in insignificant amounts in SKOV-3.
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specificity of the staining process, a TMA slide with 50
malignant breast tumors (kindly provided by Dept. of
Oncology, Lund, Sweden) was stained for GPER. Apply-
ing the same evaluation criteria, 28 samples (56%) were
positive. In addition, we found that 25/50 (50%) GPER
positive tumors were also positive for ERa, but the cor-
relation coefficient was not significant.
Discussion
This is the first study that quantifies GPER expression in
benign, borderline, and malignant ovarian tumors using
qPCR and Western blot. One study, which previously
described GPER expression in ovarian tumors [20], used
IHC as the only method. GPER expression has also
been reported in cell lines derived from various repro-
ductive organ tumors, like ovarian cancer [10].
Since, apparently, about one third of malignant sam-
ples showed high GPER expression in qPCR and Wes-
tern blot, we wished to explore the possibility that this
third might have a different clinical outcome than the
low-expressing two thirds. In our prospective popula-
tion-based TMA study of 150 malignant primary
tumors, one third of the tumors had significant staining.
However, this third was not distinguished from the
negative samples by any of the clinical parameters i.e.
stage of the disease, histological grade, and over-all
Figure 4 Western blot of GPER in ovarian tumors with semi-quantification A) GPER protein was detected as a single band at 54 kDa
in Western blots of primary ovarian tumor extracts. Abbreviations are as in Figure 1. NC = negative control (extract from HEK-293 cells). B)
The tissue content of GPER protein was semi-quantified by densitometric scanning of the bands, and presented as integrated optical density
(IOD). The number of samples (n) in each group is given in the graph. GPER protein levels were not different between benign/borderline tumors
and malignant tumors, although G3 tumors had higher level than benign tumors (p = 0.03). However, the number of samples with elevated
GPER protein (> 500 arbitrary cut-off) was higher in malignant (10/24) than in benign/borderline tumors (1/16), (p = 0.01, Fisher’s exact test).
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survival. This finding disagrees with the results of Smith
et al., who reported that high GPER expression was
associated with high histological grade and clinical stage
as well as poor survival in an IHC study of 89 malignant
and 45 borderline ovarian tumors [20]. Furthermore,
another two IHC studies observed correlation between
GPER and unfavorable clinicopathological features. One
study with a large number of malignant breast tumors
showed that over-expression of GPER protein was asso-
ciated with poor prognostic parameters like large tumor
size, distant metastases, and over-expression of HER2
[21]. The other study on primary endometrial cancer
reported that over-expression of GPER protein in the
tumor tissue correlated with poor differentiation, aggres-
sive subtype, and advanced clinical stage [22]. However,
in this context it should also be noted that another
study of GPER mRNA in breast cancer tissue failed to
identify any correlation between the level of expression
and clinical parameters [23].
Generally, discrepancies between immunohistochem-
ical studies may relate to different populations studied,
tissue handling and processing, specificity and sensitivity
of the primary antibody, characteristics of the detection
system, criteria used in the evaluation process, etc. We
employed the GPER antibody we considered most reli-
able among those commercially available and used it in
two methods. In Western blot, this antibody gave one
band in all tumor samples. Densitometric scanning
found the band to be strong in about one third of the
samples. In IHC, our evaluation of TMA found roughly
one third of samples positive. Thus, our Western Blot
and IHC results revealed similar fraction of high-expres-
sing/positive samples. In addition, these data derive sup-
port from our qPCR results. Comparison with other
Figure 5 Distribution of GPER immunohistochemical staining in serous, mucinous and endometrioid ovarian tumors Altogether 37
samples were evaluated. Abbreviations are as in Figure 1. Non-immune IgG replaced the GPER antibody as a negative control (NC). Staining
was mainly localized in tumor cells, but also in single stromal cells. It tended to be strongest in tumor cells close to the stroma. Staining could
be identified both in cell membranes and in the cytoplasm.
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methods was not done in previously mentioned IHC
studies.
To check sensitivity of the antibody, we included a
TMA slide with 50 breast tumors in a control experi-
ment. After an identical staining process we found that
about 60% of the samples were positive, which is com-
parable to that reported in previous study of breast can-
cer [21]. Hence the fraction of GPER positive samples
was smaller in ovarian tumors than in breast tumors. In
fact, GPER seems to be involved in both proliferative
and anti-proliferative effects, which are tissue specific
[24-26].
We found that GPER immune staining was mainly
localized in the malignant epithelial cells, although focal
weak staining as well as single cell staining was also pre-
sent in the stroma. This distribution matches above-
mentioned IHC studies of reproductive malignancies,
and it is also similar to the GPER distribution we and
others previously reported in normal human endome-
trial tissue [11,18]. Even though epithelial distribution of
GPER is a common feature in female reproductive
organs and their tumors, GPER is also expressed in
other cell types in these organs. In the malignant cells,
we found GPER staining both in the plasma membrane
and in the cytoplasm. This is in agreement with a pre-
vious study, which identified intracellular GPER traffick-
ing between the plasma membrane and cytokeratin
intermediate filaments [8]. Interestingly, Smith et al. did
not report membrane staining, but found nuclear stain-
ing together with cytoplasmic staining [20].
Expression of the two nuclear estrogen receptors had
opposite patterns in ovarian tumors, i.e. ERa mRNA
was higher whereas ERb mRNA was lower in malignant
tumors, while the reverse relation was seen in benign
tumors. In fact, our results are supported by similar
findings in a previous mRNA study of ERa and ERb in
ovarian tumors [27], and this seems to adhere to the
general principle that ERa increases and ERb decreases
with loss of histological differentiation. The expression
of GPER mRNA had a different pattern than that of
ERa mRNA and ERb mRNA since it showed no signifi-
cant difference between the benign, borderline and
malignant tumors. However, there was a weak correla-
tion between GPER and ERa mRNA. Such similarity
between these mRNA expressions, which we previously
observed in normal human endometrium [18], has also
Figure 6 Tumor tissue content of GPER related to histological and clinical parameters TMA of 150 malignant primary ovarian tumors
were immunostained for GPER. A) Each histological type and grade as well as clinical stage was stratified as GPER positive samples (score 2-9)
vs. GPER negative samples (score 0-1). The distribution of GPER positive samples was not different between histological types, differentiation
grades, or clinical stages. B) Kaplan-Meier curves of overall survival for patients showed no difference between GPER positive and GPER negative
tumors.
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been reported in breast cancer [21,23,28]. Interestingly,
GPER and ERb had very similar pattern of mRNA
expression in the seven ovarian cancer cell lines,
whereas ERa mRNA was expressed in only three out of
seven ovarian cancer cell lines, and only at a low level.
Proliferation in ovarian cancer cells is influenced by
estrogen. BG-1 ovarian cancer cells, which express both
GPER and ERa, respond to both estradiol and to a selec-
tive GPER agonist G-1 with induced expression of c-fos
and cyklins D1, E, and A [10]. Noticeably, both GPER
and ERa were needed for the response, also when cells
were stimulated with G1. Furthermore, inhibition of the
EGFR transduction pathway inhibited c-fos stimulation
and ERK activation by both ligands, supporting previous
reports that GPER activation and signaling involves
trans-activation of the EGFR [9]. GPER may thus play a
role in cancer cell proliferation possibly through trans-
activation of EGFR, or as an ERa collaborator. However,
GPER is also known to mediate ERa antagonizing effects
depending on the cell/tissue type [29].
GPER is further involved in ovarian cancer cell migra-
tion. Using a trans-membrane migration assay, we found
that EGF stimulated migration in seven ovarian cancer
cell lines (same as used in this study), and that this
resulted from increased cell surface expression of ligated
uPAR. In contrast to Park et al. [30], we did not find a
direct effect of estradiol on migration in any of the
seven ovarian cancer cell lines [31]. However, estradiol
attenuated the stimulatory effect of EGF on migration in
all seven cell lines [31] through inhibition of EGF-
induced accumulation of detergent extractable uPAR.
Furthermore, since Tamoxifen and ICI 182780, antago-
nists to nuclear ERs, and G-1, a specific GPER agonist,
mimicked this effect of estradiol, we concluded that
estrogen modulation of EGF induced migration in ovar-
ian cancer cells was mediated by GPER, not by ERa.
Since expression of the EGF system in ovarian tumors
relates to poor prognosis as well as to poor response to
chemotherapy [32,33], and estradiol mediated activation
of GPER attenuates the invasive properties resulting
from EGF stimulation [31], a GPER agonist could have
therapeutic implications in patients with ovarian cancer.
On the other hand, our present study shows that GPER
is neither a suitable diagnostic marker, since only one
third of malignant ovarian tumors have increased
expression, nor a prognostic marker, as it does not cor-
relate with patient outcome. Finally, GPER most likely
contributes to complexity of the clinical response to
SERMs, like tamoxifen, and also function as a co-player
to the nuclear ERs.
Conclusions
GPER expression, both at the mRNA and protein level,
was detectable in all tissue samples of benign, borderline
and malignant ovarian tumors. We also report that the
tumor tissue content of neither GPER mRNA nor the
protein was different between benign and malignant
tumors, although both the mRNA and the protein were
over-expressed in about one third of the malignant
tumors. However, this GPER positive third of malignant
ovarian tumors had no relation to clinical parameters.
Abbreviations
GPER: GPR30, G protein-coupled estrogen receptor, G protein-coupled
receptor 30; ERα: Estrogen receptor α; ERβ: estrogen receptor β; qPCR:
quantitative real-time PCR; TMA: Tissue Microarray; IHC:
immunohistochemistry; OS: overall survival.
Acknowledgements
Technical skills of Kristina Lövgren and Eleonor Åsander are acknowledged.
This study was supported by the Swedish Cancer Society and funding from
Skåne University Hospital and Region Skåne.
Author details
1Department of Gynecology & Obstetrics, Department of Clinical Sciences,
Lund University, Skåne University Hospital Lund, SE-221 85 Lund, Sweden.
2Division of Pathology, Department of Clinical Sciences, Lund University,
Skåne University Hospital Lund, SE-221 85 Lund, Sweden.
Authors’ contributions
ZK carried out the Western Blot analysis, part of the gene expression
experiments, evaluation of the immunohistochemical staining, statistical
analysis, and drafted the manuscript. VC contributed methodological know-
how. EH carried out the cell culture. SA extracted the total RNA and
performed a part of the qPCR analysis. AE re-evaluated the histopathology
of tumor samples and evaluated the immunohistochemical staining. KJ
supplied the TMA material and performed the histopathological re-
evaluation. BC participated in the conception and design of the study, and
drafted the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 20 January 2012 Accepted: 18 March 2012
Published: 18 March 2012
References
1. Bai W, Oliveros-Saunders B, Wang Q, Acevedo-Duncan ME, Nicosia SV:
Estrogen stimulation of ovarian surface epithelial cell proliferation. In
Vitro Cell Dev Biol Anim 2000, 36(10):657-666.
2. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC: Estradiol up-regulates
antiapoptotic Bcl-2 messenger ribonucleic acid and protein in
tumorigenic ovarian surface epithelium cells. Endocrinology 2001,
142(6):2351-2360.
3. Lindgren P, Backstrom T, Mahlck CG, Ridderheim M, Cajander S: Steroid
receptors and hormones in relation to cell proliferation and apoptosis in
poorly differentiated epithelial ovarian tumors. Int J Oncol 2001,
19(1):31-38.
4. Bardin A, Hoffmann P, Boulle N, Katsaros D, Vignon F, Pujol P, Lazennec G:
Involvement of estrogen receptor beta in ovarian carcinogenesis. Cancer
Res 2004, 64(16):5861-5869.
5. Thomas C, Gustafsson JA: The different roles of ER subtypes in cancer
biology and therapy. Nat Rev Cancer 2011, 11(8):597-608.
6. Thomas P, Pang Y, Filardo EJ, Dong J: Identity of an estrogen membrane
receptor coupled to a G protein in human breast cancer cells.
Endocrinology 2005, 146(2):624-632.
7. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER: A
transmembrane intracellular estrogen receptor mediates rapid cell
signaling. Science 2005, 307(5715):1625-1630.
8. Sanden C, Broselid S, Cornmark L, Andersson K, Daszkiewicz-Nilsson J,
Martensson UE, Olde B, Leeb-Lundberg LM: G protein-coupled estrogen
receptor 1/G protein-coupled receptor 30 localizes in the plasma
Kolkova et al. Journal of Ovarian Research 2012, 5:9
http://www.ovarianresearch.com/content/5/1/9
Page 10 of 11
membrane and traffics intracellularly on cytokeratin intermediate
filaments. Molecular pharmacology 2011, 79(3):400-410.
9. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr: Estrogen-induced
activation of Erk-1 and Erk-2 requires the G protein-coupled receptor
homolog, GPR30, and occurs via trans-activation of the epidermal
growth factor receptor through release of HB-EGF. Mol Endocrinol 2000,
14(10):1649-1660, Baltimore, Md.
10. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI,
Prossnitz ER, Musti AM, Ando S, et al: G protein-coupled receptor 30
(GPR30) mediates gene expression changes and growth response to
17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.
Cancer Res 2007, 67(4):1859-1866.
11. Gao F, Ma X, Ostmann AB, Das SK: GPR30 activation opposes estrogen-
dependent uterine growth via inhibition of stromal ERK1/2 and
estrogen receptor alpha (ERalpha) phosphorylation signals. Endocrinology
2011, 152(4):1434-1447.
12. Nodin B, Zendehrokh N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ,
Jirstrom K: Increased androgen receptor expression in serous carcinoma
of the ovary is associated with an improved survival. Journal of ovarian
research 2010, 3:14.
13. Ehlen A, Nodin B, Rexhepaj E, Brandstedt J, Uhlen M, Alvarado-
Kristensson M, Ponten F, Brennan DJ, Jirstrom K: RBM3-regulated genes
promote DNA integrity and affect clinical outcome in epithelial ovarian
cancer. Translational oncology 2011, 4(4):212-221.
14. Ehlen A, Brennan DJ, Nodin B, O’Connor DP, Eberhard J, Alvarado-
Kristensson M, Jeffrey IB, Manjer J, Brandstedt J, Uhlen M, et al: Expression
of the RNA-binding protein RBM3 is associated with a favourable
prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl
Med 2010, 8:78.
15. Brennan DJ, Brandstedt J, Rexhepaj E, Foley M, Ponten F, Uhlen M,
Gallagher WM, O’Connor DP, O’Herlihy C, Jirstrom K: Tumour-specific HMG-
CoAR is an independent predictor of recurrence free survival in
epithelial ovarian cancer. BMC Cancer 2010, 10:125.
16. Nodin B, Fridberg M, Uhlen M, Jirstrom K: Discovery of Dachshund 2
protein as a novel biomarker of poor prognosis in epithelial ovarian
cancer. Journal of ovarian research 2012, 5(1):6.
17. Noskova V, Ahmadi S, Asander E, Casslen B: Ovarian cancer cells stimulate
uPA gene expression in fibroblastic stromal cells via multiple paracrine
and autocrine mechanisms. Gynecol Oncol 2009, 115(1):121-126.
18. Kolkova Z, Noskova V, Ehinger A, Hansson S, Casslen B: G protein-coupled
estrogen receptor 1 (GPER, GPR 30) in normal human endometrium and
early pregnancy decidua. Molecular human reproduction 2010,
16(10):743-751.
19. Jogi A, Brennan DJ, Ryden L, Magnusson K, Ferno M, Stal O, Borgquist S,
Uhlen M, Landberg G, Pahlman S, et al: Nuclear expression of the RNA-
binding protein RBM3 is associated with an improved clinical outcome
in breast cancer. Mod Pathol 2009, 22(12):1564-1574.
20. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ,
Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER: GPR30 predicts poor
survival for ovarian cancer. Gynecologic oncology 2009, 114(3):465-71.
21. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, Delellis RA,
Steinhoff MM, Sabo E: Distribution of GPR30, a Seven Membrane-
Spanning Estrogen Receptor, in Primary Breast Cancer and its
Association with Clinicopathologic Determinants of Tumor Progression.
Clin Cancer Res 2006, 12(21):6359-6366.
22. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE,
Prossnitz ER: GPR30: a novel indicator of poor survival for endometrial
carcinoma. Am J Obstet Gynecol 2007, 196(4):386 e381-386 e389, discussion
386 e389-311.
23. Kuo WH, Chang LY, Liu DL, Hwa HL, Lin JJ, Lee PH, Chen CN, Lien HC,
Yuan RH, Shun CT, et al: The interactions between GPR30 and the major
biomarkers in infiltrating ductal carcinoma of the breast in an Asian
population. Taiwan J Obstet Gynecol 2007, 46(2):135-145.
24. Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM, Lau KM:
Activation of GPR30 inhibits the growth of prostate cancer cells through
sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of
p21, and induction of G(2) cell-cycle arrest. Cell Death Differ 2010,
17(9):1511-1523.
25. Holm A, Baldetorp B, Olde B, Leeb-Lundberg LM, Nilsson BO: The GPER1
agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA
synthesis and accumulating cells in the S and G2 phases of the cell
cycle. J Vasc Res 2011, 48(4):327-335.
26. Lin BC, Suzawa M, Blind RD, Tobias SC, Bulun SE, Scanlan TS, Ingraham HA:
Stimulating the GPR30 estrogen receptor with a novel tamoxifen
analogue activates SF-1 and promotes endometrial cell proliferation.
Cancer Res 2009, 69(13):5415-5423.
27. Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, Ngan HY: Estrogen
receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol
2008, 111(1):144-151.
28. Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A,
Roessner A, Costa SD, Kalinski T: G-protein-coupled estrogen receptor
GPR30 and tamoxifen resistance in breast cancer. Breast cancer research
and treatment 2011, 128(2):457-466.
29. Teng J, Wang ZY, Prossnitz ER, Bjorling DE: The G protein-coupled
receptor GPR30 inhibits human urothelial cell proliferation. Endocrinology
2008, 149(8):4024-4034.
30. Park SH, Cheung LW, Wong AS, Leung PC: Estrogen regulates Snail and
Slug in the down-regulation of E-cadherin and induces metastatic
potential of ovarian cancer cells through estrogen receptor alpha. Mol
Endocrinol 2008, 22(9):2085-2098, Baltimore, Md.
31. Henic E, Noskova V, Hoyer-Hansen G, Hansson S, Casslen B: Estradiol
attenuates EGF-induced rapid uPAR mobilization and cell migration via
the G-protein-coupled receptor 30 in ovarian cancer cells. Int J Gynecol
Cancer 2009, 19(2):214-222.
32. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL,
Bast RC Jr: Epidermal growth factor receptor expression in normal
ovarian epithelium and ovarian cancer. I. Correlation of receptor
expression with prognostic factors in patients with ovarian cancer. Am J
Obstet Gynecol 1991, 164(2):669-674.
33. Scambia G, Benedetti-Panici P, Ferrandina G, Distefano M, Salerno G,
Romanini ME, Fagotti A, Mancuso S: Epidermal growth factor, oestrogen
and progesterone receptor expression in primary ovarian cancer:
correlation with clinical outcome and response to chemotherapy. Br J
Cancer 1995, 72(2):361-366.
doi:10.1186/1757-2215-5-9
Cite this article as: Kolkova et al.: The G protein-coupled estrogen
receptor 1 (GPER/GPR30) does not predict survival in patients with
ovarian cancer. Journal of Ovarian Research 2012 5:9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kolkova et al. Journal of Ovarian Research 2012, 5:9
http://www.ovarianresearch.com/content/5/1/9
Page 11 of 11
